In the last trading session, 1.84 million Verve Therapeutics Inc (NASDAQ:VERV) shares changed hands as the company’s beta touched 1.68. With the company’s per share price at $5.25 changed hands at -$0.25 or -4.55% during last session, the market valuation stood at $444.48M. VERV’s last price was a discount, traded about -268.38% off its 52-week high of $19.34. The share price had its 52-week low at $4.30, which suggests the last value was 18.1% up since then. When we look at Verve Therapeutics Inc’s average trading volume, we note the 10-day average is 1.24 million shares, with the 3-month average coming to 1.48 million.
Analysts gave the Verve Therapeutics Inc (VERV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended VERV as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Verve Therapeutics Inc’s EPS for the current quarter is expected to be -0.67.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Instantly VERV was in red as seen at the end of in last trading. With action -18.10%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -6.91%, with the 5-day performance at -18.10% in the red. However, in the 30-day time frame, Verve Therapeutics Inc (NASDAQ:VERV) is -16.67% down. Looking at the short shares, we see there were 14.21 million shares sold at short interest cover period of 8.43 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 62.5% from its current market value. According to analyst projections, VERV’s forecast low is 14 with 14 as the target high. To hit the forecast high, the stock’s price needs a -166.67% plunge from its current level, while the stock would need to soar -166.67% for it to hit the projected low.
Verve Therapeutics Inc (VERV) estimates and forecasts
Data shows that the Verve Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -26.68% over the past 6 months, a 20.19% in annual growth rate that is considerably higher than the industry average of 16.30%. Year-over-year growth is forecast to reach 102.87% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 4.94M. 4 analysts are of the opinion that Verve Therapeutics Inc’s revenue for the current quarter will be 3.97M. The company’s revenue for the corresponding quarters a year ago was 5.14M and 5.7M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -3.87%. The estimates for the next quarter sales put growth at -30.36%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -67.06%. The 2025 estimates are for Verve Therapeutics Inc earnings to increase by 21.25%.
VERV Dividends
Verve Therapeutics Inc is expected to release its next quarterly earnings report in February.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.29% of Verve Therapeutics Inc shares while 97.91% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.37%. There are 97.91% institutions holding the Verve Therapeutics Inc stock share, with ALPHABET INC. the top institutional holder. As of 2024-06-30, the company held 14.8546% of the shares, roughly 12.35 million VERV shares worth $60.26 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.9632% or 6.62 million shares worth $32.31 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund . With 2.27 shares estimated at $11.91 million under it, the former controlled 2.68% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.54% of the shares, roughly 2.15 shares worth around $11.31 million.
